Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial

Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial

Background Over 70% of the patients with hepatocellular carcinoma (HCC) are diagnosed at an advanced stage and lose the opportunity for radical surgery. Combination therapy of tyrosine kinase inhibitors (TKIs) and anti-programmed cell death protein-1 (PD-1) antibodies has achieved a high tumor respo...

Full description

Bibliographic Details
Main Authors: Ze Zhang, Wenwen Zhang, Mingyi Chen, Hongguang Wang, Tao Wan, Bingyang Hu, Shichun Lu, Zhanbo Wang, Xiaochen Zhao, Yuezong Bai, Yafei Wang, Xuerui Li, Shiqing Chen, Feilong Zhao, Jinping Cai, Shuang Tong, Haowen Tang, Tianyu Jiao, Junfeng Li, Huiyi Ye, Fangzhou Wang, Junning Cao, Lantian Tian, Shouwang Cai, Minggen Hu
Format: Article
Language:English
Published: BMJ Publishing Group 2023-09-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/11/9/e007366.full

Internet

https://jitc.bmj.com/content/11/9/e007366.full

Similar Items